AUPH News and Press, Aurinia Pharmaceuticals Inc From 11/02/23

2023-11-02 12:06:10 ET Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Conference Call November 02, 2023, 08:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer ...

2023-11-02 10:51:47 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Reassessing As It Gains Traction Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade) Aurinia Pharma Q3 2023 Earnings Preview Aurinia reaches truce with major shareholder ...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

2023-11-02 06:02:25 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Reassessing As It Gains Traction Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade) Aurinia Pharma Q3 2023 Earnings Preview Aurinia reaches truce with major shareholder ...

Net product revenue of $40.8 million for the third quarter of 2023; an increase of 60% over the prior year third quarter Total net revenue of $130.4 million for the nine months ended September 30, 2023, an increase of 24% over prior year Achieved European pricing and reimbursement...

Aurinia Pharmaceuticals Inc (AUPH) is expected to report $-0.17 for Q3 2023

2023-11-01 13:08:32 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Reassessing As It Gains Traction Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade) Aurinia reaches truce with major shareholder in new board appointment Seeking Alpha&#...

Recommendations Published online in Annals of the Rheumatic Diseases Propose That Physicians Consider Earlier Intervention with Therapies Including LUPKYNIS ® (voclosporin) as a New LN Treatment Paradigm Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) &...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2023, on Thursday, November 2, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from 14 studies of LUPKYNIS ® (voclosporin) wi...